



**COUNCIL OF  
THE EUROPEAN UNION**

**Brussels, 13 May 2013**

**9306/13**

**CORDROGUE 31**

**OUTCOME OF PROCEEDINGS**

---

of:	Meeting of the Horizontal Working Party on Drugs
on:	18 April 2013
Subject:	Summary of discussions

---

**1. Adoption of the agenda**

The agenda set out in document CM 2261/13 was approved with the addition of the following information points under AOB:

- Combating drugs at the international level;
- Call for proposals for DPIP programme;
- New legislation to address new psychoactive substances.

**2. Information concerning the proceedings of other EU bodies**

The HDG was updated about some recent events of relevance to antidrug policy, including the progress achieved in the examination of proposed amendments to drug precursor legislation, the discussion on the priorities of the new policy cycle and the proposal to establish the Bogota platform to exchange strategic and operative information, which was supported by a number of delegations who found the current platforms a useful instrument. The Presidency also informed the meeting about an initiative to organise a joint HDG and COLAT meeting and invited all interested HDG delegations to participate.

### **3. Discussion on the draft EU Drugs Action Plan 2013-2016**

The delegations further discussed the draft Action Plan, outlined in doc. 5418/2/13 REV 2 CORDROGUE 5 SAN 18 ENFOPOL 12 RELEX 42, which was more focused and contained a reduced number of actions compared to the previous version. It was clarified that the Commission would prepare one 2-year report covering the implementation of various actions of the Action Plan, rather than separate reports. The Presidency announced that at the May HDG meeting the delegations would be invited to endorse the draft Action Plan taking into account the comments delivered during this meeting with a view to submitting it to COREPER/Council.

### **4. Study "Further insights into aspects of the EU illicit drugs market"**

The representative of the Trimbos Institute presented the above-mentioned study available at [http://ec.europa.eu/justice/anti-drugs/files/eu\\_market\\_full.pdf](http://ec.europa.eu/justice/anti-drugs/files/eu_market_full.pdf) (full version, summary and key findings can be found at [http://ec.europa.eu/justice/anti-drugs/files/eu\\_market\\_summary\\_en.pdf](http://ec.europa.eu/justice/anti-drugs/files/eu_market_summary_en.pdf)). In response to delegations, it was clarified that a different methodology was used for conducting this study and the recent EMCDDA/Europol study on drug market. The first study explored the drugs market from the consumers' perspective, therefore providing a different output.

### **5. Drug supply indicators**

The representative of the Commission and EMCDDA explained the importance of having drug supply indicators and reminded actions already taken to develop them, outlined in doc. DS 1249/13. Some delegations welcomed the work undertaken, while a few other raised doubts about the process and indicators proposed. In response to delegations, it was explained that the relevant information was already provided by Member States to the EMCDDA, but needed to be made comparable. Therefore, the EMCDDA was intending to do that step by step and the development of these comparable indicators would not represent an additional burden for the Member States. As the first practical step towards the development of these indicators the delegations were asked to designate a national contact point with expertise in drug supply and also to provide comments on the topic by 30 April 2013.

## **6. Report on the EU-Western Balkans expert meeting on drugs**

The Presidency reported on the above-mentioned meeting held on 26 February 2013 (see doc. 7297/13 CORDROGUE 26 COWEB 34).

## **7. Commission on Narcotic Drugs**

The Presidency gave an overview of the outcome of the 56<sup>th</sup> CND session, outlining the EU work and the role of civil society in the proceedings of the session. The importance of the early discussion (possibly starting at the end of the year) on draft EU resolutions at the HDG was stressed noting that third country resolutions could also be examined at the HDG. The Presidency proposed holding a discussion on the principles of preparation and participation in the future CND sessions at some forthcoming HDG meeting.

## **8. Report on the EU National Drugs Coordinators meeting**

The Presidency gave an overview of the above-mentioned meeting held on 8-9 April 2013 in Dublin, which dealt with a number of drug demand reduction related issues, and informed the delegates that the following challenges were raised during the meeting: providing access to treatment for marginalised groups, benefitting from inter-agency work and developing drug policy in the time of economic austerity.

## **9. EU-CELAC Mechanism on Drugs**

The Presidency gave an overview of the first EU-CELAC Technical Committee meeting, held on 17 April 2013 (see doc. 9307/13 CORDROGUE 32 COLAT 12 AMLAT 9) and the preparations for the High Level meeting to be held on 13-14 June 2013 in Quito and encouraged delegations to participate in it. It was also announced that the COPOLAD would finance the airplane ticket for one delegate from each EU Member State to participate in the Annual COPOLAD Conference to be held on 11-12 June in Quito, and this ticket could also be used for participation in the EU-CELAC High Level meeting.

## **10. Preparation for the EU-US expert meeting on drugs**

The Presidency presented the agreed agenda of the above-mentioned meeting to be held on 15 May 2013, contained in doc. DS 1250/1/13 REV 1 and also noted that the US inquired about a possibility to hold this meeting as a videoconference.

## **11. Proposed shared session/event involving the EU Civil Society Forum on Drugs and the HDG**

The representative of the Commission informed the delegations about the initiative to hold the above-mentioned event and delegations widely supported this initiative suggesting to hold the meeting on 25 June 2013. The speaker promised to discuss the possible format of the meeting with the representatives of the Forum and to report on that during the forthcoming HDG meeting.

## **12. SOCTA 2013 report**

The representative of EUROPOL presented the drug-related aspects of the recent SOCTA report, contained in doc. 7368/13 JAI 200 COSI 26 ENFOPOL 75 CRIMORG 41 CORDROGUE 27 ENFOCUSTOM 43 PESC 286 JAIEX 20 RELEX 211 + COR 1.

## **13. Renewal of the EU-Central Asia Action Plan on Drugs**

The representative of the EEAS gave an overview of the proceedings and outcomes of the CADAP 5 final conference, reminding that for the first time CADAP 5 was launched fully under EU lead and obtained substantial results in each Central Asian country and regionally. It was also announced that CADAP 6 was ready for launching and the call for expression of interest should be circulated soon.

The speaker informed the meeting that the main elements of the draft updated EU-Central Asia action plan on drugs, contained in doc. DS 1222/1/13 REV 1, were also presented during the meeting and were well received by the Central Asia partners. The representative stressed that the EU Drugs Strategy had become a major point of reference for Central Asian states in achieving concrete results.

## 14. AOB

### - *Efforts of the Slovak Republic towards reducing the production of Methamphetamine*

The SK delegation informed the meeting about the efforts to tackle the production of methamphetamine by proposing to schedule red phosphorus, the critical ingredient for the production of methamphetamine, in subcategory 2A of Regulation (EC) No 273/2004 on drug precursors, where not only operators but also users should be subject to a registration requirement. Slovakia asked for Member States' support.

### - *Combating drugs at the international level*

The FR delegation informed the meeting about the above-mentioned initiative aimed at making additional efforts and better tackling drugs at international level using the existing legal instruments. It was proposed to hold a meeting of the Heads of States and Governments in the margin of the next UNGA in September 2013 to examine the impact of drug trafficking on the stability of states, which would contribute to the review of the UN Political declaration in 2014 and a special UNGASS session on drugs in 2016. France is keen on consulting its European partners on a potential EU contribution. The issue of border control and maritime surveillance should be raised within the EU framework.

### - *Call for proposals for DPIIP programme*

The representative of the Commission announced that new calls for proposals would be launched under DPIIP before summer 2013 and asked the delegations to advise potential beneficiaries in their Member States.

### - *New legislation to address new psychoactive substances*

The PT delegation informed the meeting about a new decree providing a legal framework for advertisement and distribution of new psychoactive substances, listing these substances which would become subject to control.